Archive — US — techcrunch
Elizabeth Holmes’ partner reportedly fundraising for new blood-testing startup
Billy Evans, partner of Elizabeth Holmes, is raising funds for a new blood-testing startup named Haemanthus, which aims to optimize human health through advanced testing methods. The startup plans to analyze blood and other biological samples to detect diseases, starting with pets. This venture reminds many of Theranos, as it seeks over $50 million despite Holmes' recent conviction for fraud.
Key points
- Billy Evans is working on a blood-testing startup called Haemanthus.
- Haemanthus aims to deliver health optimization by analyzing blood, saliva, and urine samples.
- The startup plans to target pet health before expanding to humans.
- It is seeking to raise more than $50 million from investors.
- The initiative draws parallels to Theranos, as both promise advanced testing with minimal samples.
- Elizabeth Holmes, co-founder of Theranos, was sentenced to 11 years in prison for investor fraud.
- An early investor for Facebook declined to invest in Haemanthus, citing concerns similar to those with Theranos.
Why it matters
- The rise of health tech startups continues amid growing interest in personalized healthcare solutions.
- In the wake of Theranos, investors are increasingly cautious and demand rigorous validation of medical claims.
- Current trends in healthcare innovation focus on AI and advanced diagnostics, reflecting a shift toward technology-driven solutions.
The formation of Haemanthus by Evans highlights ongoing interest in the healthcare technology sector, but the shadow of Theranos raises questions about credibility, investor caution, and the future of health startup funding.